| Literature DB >> 15766663 |
Ronit Satchi-Fainaro1, Roni Mamluk, Ling Wang, Sarah M Short, Janice A Nagy, Dian Feng, Ann M Dvorak, Harold F Dvorak, Mark Puder, Debabrata Mukhopadhyay, Judah Folkman.
Abstract
Angiogenesis inhibitors, such as TNP-470 and the nontoxic HPMA copolymer-TNP-470 (caplostatin), are emerging as a class of anticancer drugs. We report that TNP-470 and caplostatin inhibit vascular hyperpermeability of tumor blood vessels as well as that induced in mouse skin by different mediators. Treatment with TNP-470 or angiostatin for 3 days was sufficient to reduce permeability of tumor blood vessels, delayed-type hypersensitivity, and pulmonary edema induced by IL-2. TNP-470 also inhibited VPF/VEGF-induced phosphorylation of VEGFR-2, calcium influx, and RhoA activation in endothelial cells. These results identify an activity of TNP-470, that of inhibiting vessel hyperpermeability. This activity likely contributes to TNP-470's antiangiogenic effect and suggests that caplostatin can be used in the treatment of cancer and inflammation.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15766663 DOI： 10.1016/j.ccr.2005.02.007
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743